Always nice to see great execution all the way through. Today, Biohaven will begin to trade on the NYSE under the ticker symbol BHVN. The company has successfully raised $168 Million. Portage, $PTGEF will own approximately 28% of the equity in Biohaven.
Biotech continues to be a very hot sector with copious amounts of money pouring in.
Small float, lots of interest and stage 3 clinical set this one up for a nice run.
Any shares under $22 are a steal. No reason why a 2X return is not in the cards rather quickly.
Word of caution: Biotech shares can be extremely volatile. Be wary, be nimble.
Biohaven is a clinical-stage bio pharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has licensed intellectual property from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is a company organized under the laws of the British Virgin Islands and its United States operations are based in New Haven, Connecticut.
Portage is engaged in the discovery and development of pharmaceutical and biotech products through clinical “proof of concept” with a focus on areas of unmet clinical need. Following proof of concept, Portage will seek to sell or license these products to large pharmaceutical or biotechnology companies for further development and commercialization. Portage has an interest in novel targeted therapies, stem cell therapies, and new indications for older marketed products that have been found to have novel patentable characteristics that bring new value to patients.
Portage has been my micro-cap biotech favorite and it has performed incredibly well having moved from $0.07 to a current $.36. Still has much more room on the upside in my opinion.
Kudos to Dr. Greg Bailey for having the big vision and executing upon it.